Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Roche (ROG.SW) and Zealand Pharma (ZEAL.CO) stocks are in focus after the company announced an agreement to make amylin, an obesity drug, in a deal valued at $5.3 billion. Yahoo Finance Senior ...
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.
Livewire Markets on MSN6d
The 4 biotech firms the experts are most excited aboutThe biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Zacks Investment Research on MSN3d
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss DrugViking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...
Company announcement - No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078) ...
No. 6 / 2025Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback